Biomarkers and Evolution in Alzheimer Disease

Overview

Journal Prog Neurobiol

Specialty Neurology

Date 2011 Aug 2

PMID 21801803

Citations 21

Authors

Stanley I Rapoport

Peter T Nelson

Affiliations

Soon will be listed here.

Abstract

Brain regions and their highly neuroplastic long axonal connections that expanded rapidly during hominid evolution are preferentially affected by Alzheimer disease. There is no natural animal model with full disease pathology (neurofibrillary tangles and neuritic amyloid plaques of a severity seen in Alzheimer's disease brains). Biomarkers such as reduced glucose metabolism in association neocortex, defects in long white matter tracts, RNA neurochemical changes, and high CSF levels of total and phosphorylated tau protein, which are helpful to identify MCI and preclinical Alzheimer disease patients, may also provide insights into what brain changes led to this disease being introduced during hominid evolution.

Citing Articles

Amyloid-Beta, Tau, and Microglial Activation in Aged Felid Brains.

Kulik V, Edler M, Raghanti M, Imam A, Sherwood C J Comp Neurol. 2024; 532(11):e25679.

PMID: 39474737 PMC: 11572721. DOI: 10.1002/cne.25679.

Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid.

Abukuri D Int J Alzheimers Dis. 2024; 2024:6668159.

PMID: 38779175 PMC: 11111307. DOI: 10.1155/2024/6668159.

Bearded capuchin monkeys as a model for Alzheimer's disease.

Rodriguez R, Tavares M, Brucki S, Takada L, Garcia Otaduy M, Martin M Sci Rep. 2024; 14(1):6287.

PMID: 38491154 PMC: 10943096. DOI: 10.1038/s41598-024-56791-y.

Bearded capuchin monkey as a model for Alzheimer's disease research.

Rodriguez R, Tavares M, Brucki S, Takada L, Otaduy M, Martin M Res Sq. 2023; .

PMID: 38106066 PMC: 10723548. DOI: 10.21203/rs.3.rs-3495799/v1.

Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey.

Chan A, Cho I, Li C, Zhang X, Patel S, Rusnak R Aging Brain. 2023; 2.

PMID: 36589695 PMC: 9802652. DOI: 10.1016/j.nbas.2022.100044.

References

Hampel H, Blennow K, Shaw L, Hoessler Y, Zetterberg H, Trojanowski J . Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. 2009; 45(1):30-40. PMC: 2815003. DOI: 10.1016/j.exger.2009.10.010. View

Hatanpaa K, Brady D, Stoll J, Rapoport S, Chandrasekaran K . Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1996; 40(3):411-20. DOI: 10.1002/ana.410400310. View

Haxby J, Grady C, Koss E, Horwitz B, Heston L, Schapiro M . Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990; 47(7):753-60. DOI: 10.1001/archneur.1990.00530070043010. View

Fleisher A, Raman R, Siemers E, Becerra L, Clark C, Dean R . Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008; 65(8):1031-8. PMC: 2682361. DOI: 10.1001/archneur.65.8.1031. View

Kumar A, Schapiro M, Grady C, Haxby J, Wagner E, Salerno J . High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology. 1991; 4(1):35-46. View

Braak H, Braak E . Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996; 92(2):197-201. DOI: 10.1007/s004010050508. View

Di Patre P . Cytoskeletal alterations might account for the phylogenetic vulnerability of the human brain to Alzheimer's disease. Med Hypotheses. 1991; 34(2):165-70. DOI: 10.1016/0306-9877(91)90187-4. View

DeKosky S, Scheff S, Styren S . Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration. 1996; 5(4):417-21. DOI: 10.1006/neur.1996.0056. View

Reiman E, Chen K, Alexander G, Caselli R, Bandy D, Osborne D . Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2003; 101(1):284-9. PMC: 314177. DOI: 10.1073/pnas.2635903100. View

10.

Gilbert S, Dobyns W, Lahn B . Genetic links between brain development and brain evolution. Nat Rev Genet. 2005; 6(7):581-90. DOI: 10.1038/nrg1634. View

11.

Ho L, Fivecoat H, Wang J, Pasinetti G . Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp Gerontol. 2009; 45(1):15-22. PMC: 2840994. DOI: 10.1016/j.exger.2009.09.007. View

12.

Ginsberg L, Atack J, Rapoport S, GERSHFELD N . Regional specificity of membrane instability in Alzheimer's disease brain. Brain Res. 1993; 615(2):355-7. DOI: 10.1016/0006-8993(93)90050-w. View

13.

Evans P, Anderson J, Vallender E, Choi S, Lahn B . Reconstructing the evolutionary history of microcephalin, a gene controlling human brain size. Hum Mol Genet. 2004; 13(11):1139-45. DOI: 10.1093/hmg/ddh126. View

14.

Igarashi M, Ma K, Gao F, Kim H, Rapoport S, Rao J . Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis. 2011; 24(3):507-17. PMC: 3175096. DOI: 10.3233/JAD-2011-101608. View

15.

Wang W, Rajeev B, Stromberg A, Ren N, Tang G, Huang Q . The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008; 28(5):1213-23. PMC: 2837363. DOI: 10.1523/JNEUROSCI.5065-07.2008. View

16.

Zollikofer C, Ponce de Leon M . The evolution of hominin ontogenies. Semin Cell Dev Biol. 2009; 21(4):441-52. DOI: 10.1016/j.semcdb.2009.10.012. View

17.

Rapoport S . Hypothesis: Alzheimer's disease is a phylogenetic disease. Med Hypotheses. 1989; 29(3):147-50. DOI: 10.1016/0306-9877(89)90185-0. View

18.

Nelson P, Stefansson K, Gulcher J, Saper C . Molecular evolution of tau protein: implications for Alzheimer's disease. J Neurochem. 1996; 67(4):1622-32. DOI: 10.1046/j.1471-4159.1996.67041622.x. View

19.

Rapoport S . How did the human brain evolve? A proposal based on new evidence from in vivo brain imaging during attention and ideation. Brain Res Bull. 1999; 50(3):149-65. DOI: 10.1016/s0361-9230(99)00095-7. View

20.

Mentis M, Alexander G, Krasuski J, Pietrini P, Furey M, Schapiro M . Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry. 1998; 155(6):785-94. DOI: 10.1176/ajp.155.6.785. View